Larvol Delta - Arch-Oncology-Receives-US-FDA-Orphan-Drug-Designation-for-AO176-a-NextGeneration-AntiCD47-IgG2-Antibody-for-the-Treatment-of-Multiple-Myeloma

AO-176 - Arch Oncology

https://www.globenewswire.com/news-release/2022/01/21/2370888/0/en/Arch-Oncology-Receives-U-S-FDA-Orphan-Drug-Designation-for-AO-176-a-Next-Generation-Anti-CD47-IgG2-Antibody-for-the-Treatment-of-Multiple-Myeloma.html

Jan 21, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next